Managing Adverse Events: Ponatinib & Asciminib in CML: Expert Approaches

Panelists discuss how clinicians should implement regular cardiovascular monitoring and dose modifications for ponatinib-associated toxicities while being vigilant for asciminib’s key adverse events, including thrombocytopenia, pancreatic dysfunction, and hypertension, with appropriate dose adjustments and supportive care as needed.

EP: 1.Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

EP: 2.Interpreting Milestones: Prioritizing the Patient Picture

EP: 3.Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

EP: 4.Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

Now Viewing

EP: 5.Managing Adverse Events: Ponatinib & Asciminib in CML: Expert Approaches

EP: 6.Choosing First-Line TKI Therapy for CML: Expert Approaches to Risk Assessment & Treatment Selection

Video content above is prompted by the following:

• What is your approach to monitoring and managing cardiovascular toxicities associated with ponatinib?
• What adverse events should clinicians be aware of with asciminib, and what is your approach to monitoring and managing these?

Related Videos